Metastatic breast cancer subtypes and central nervous system metastases

C. Aversa; V. Rossi; E. Geuna; R. Martinello; A. Milani; S. Redana; G. Valabrega; M. Aglietta; F. Montemurro

doi:10.1016/j.breast.2014.06.009

Metastatic breast cancer subtypes and central nervous system metastases

C. Aversa, V. Rossi, E. Geuna, R. Martinello, A. Milani, S. Redana, G. Valabrega, M. Aglietta, F. Montemurro

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (. p

Original language	English
Pages (from-to)	623-628
Number of pages	6
Journal	Breast
Volume	23
Issue number	5
DOIs	https://doi.org/10.1016/j.breast.2014.06.009
Publication status	Published - Oct 1 2014

Keywords

BC subtypes
Brain metastases
Breast neoplasms
Survival outcome

ASJC Scopus subject areas

Surgery
Medicine(all)

Access to Document

10.1016/j.breast.2014.06.009

Cite this

@article{04f5e2de4e294204b2f8146178d61e7d,

title = "Metastatic breast cancer subtypes and central nervous system metastases",

abstract = "Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (. p",

keywords = "BC subtypes, Brain metastases, Breast neoplasms, Survival outcome",

author = "C. Aversa and V. Rossi and E. Geuna and R. Martinello and A. Milani and S. Redana and G. Valabrega and M. Aglietta and F. Montemurro",

year = "2014",

month = oct,

day = "1",

doi = "10.1016/j.breast.2014.06.009",

language = "English",

volume = "23",

pages = "623--628",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "5",

}

TY - JOUR

T1 - Metastatic breast cancer subtypes and central nervous system metastases

AU - Aversa, C.

AU - Rossi, V.

AU - Geuna, E.

AU - Martinello, R.

AU - Milani, A.

AU - Redana, S.

AU - Valabrega, G.

AU - Aglietta, M.

AU - Montemurro, F.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (. p

AB - Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (. p

KW - BC subtypes

KW - Brain metastases

KW - Breast neoplasms

KW - Survival outcome

UR - http://www.scopus.com/inward/record.url?scp=84908202523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908202523&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2014.06.009

DO - 10.1016/j.breast.2014.06.009

M3 - Article

C2 - 24993072

AN - SCOPUS:84908202523

VL - 23

SP - 623

EP - 628

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -

Metastatic breast cancer subtypes and central nervous system metastases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this